HuonsMeditech, a medical device subsidiary of Huons Group, has been actively conducting academic marketing by introducing its aesthetic medical device series 'DermaShine' to domestic and international medical professionals. On May 11, 2026, HuonsMeditech announced its participation in the 'K-Beauty Advanced Technique Training Workshop (K.A.T China 2026)' and the '2026 Korean Society of Filler Medicine Spring Academic Conference'. At K.A.T China 2026, held in Shenyang, China on May 9, HuonsMeditech demonstrated skin booster procedures using the 'DermaShine Balance', a skin drug quantitative injector with over 10,000 units sold in the Chinese market, along with procedures using HuonsBioPharma's botulinum toxin formulation 'HuTox'. The company also showcased the 'Premium 9-Pin Needle', which recently received approval from China's National Medical Products Administration (NMPA).
The Premium 9-Pin Needle features a refined design structure that enhances compatibility with the device, ensuring stable procedure conditions even under high-pressure drug injection environments. By optimizing the inner diameter length of the needle tube, it enables precise injection of high-viscosity components deep into the skin without leakage, significantly reducing drug loss. Patient and practitioner convenience has also been greatly improved. A specialized bevel gear design minimizes patient pain and downtime during procedures, while a dedicated protective cap helps prevent needlestick injuries, enhancing practitioner safety. At the academic conference, HuonsMeditech focused on academic exchanges with medical professionals around the 'DermaShine Duo RF', which combines precise injection functionality with radiofrequency (RF) lifting capabilities. The DermaShine Duo RF is a device that integrates a drug injector and RF treatment into a single unit, allowing each function to be performed separately.
HuonsMeditech is pursuing expansion of its influence in global markets, including China, with the goal of strengthening global competitiveness through product development and localization strategies. "We will continue to provide academic evidence to medical professionals and demonstrate the practical utility of our products," said Ha Chang-woo, CEO of HuonsMeditech. "Through live lectures and clinical-focused programs, we aim to enhance understanding of the equipment and broaden our engagement with medical professionals."
Source: Read the original report | Published: May 11, 2026